Adc Therapeutics Sa (ADCT) Stock Price, Quote & News

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemi...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 21 653 02 00

Website: www.adctherapeutics.com

Address:

BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

Rox22 Apr. 29 at 12:41 PM

$ADCT I think they release the data and discuss in depth at their earnings call. Premarket on Monday morning is usually a bullish move. And it’s May the fourth be will you Star Wars day. Will it be A New Hope for the stock or the Empire Strikes Back or possibly The RetunS of the Jedi? Fingers crossed for the last one and we shift ADCT into the next gear.

0 · Reply

fmalad Apr. 24 at 11:18 PM

$ADCT Rumor is Data day is May 18. We should go to 5-6 right before data release then on to 8-10 if positive. Easy double from here!!!! The question is, is the CEO and hedge fund boys lining up a suitor in a timely manner!

2 · Reply

WycklyTrader Apr. 24 at 5:33 PM

$ADCT amending the HealthCare Royalty financing agreement still doesn't get rid of the "change of control" royalty cap poison pill. Weekly golden cross setup looks promising though. $XLV $IBB $LABU $LABD

0 · Reply

scalpemfast Apr. 16 at 3:18 PM

$ADCT waking up

0 · Reply

BiotechGoldenEra Apr. 16 at 2:40 AM

$ADCT wasup wasup wasup mother fucka where my money at

0 · Reply

Bdorris2 Apr. 15 at 8:43 PM

$ADCT news? I don’t see any

2 · Reply

Jay_snf Apr. 15 at 8:01 PM

$ADCT

0 · Reply

SamHot Apr. 7 at 1:36 PM

$ADCT HOLD TIGHT

0 · Reply

focafoca99 Apr. 1 at 9:48 PM

$ADCT granted a new employee inducement option covering 17,000 shares.

0 · Reply

OfficialStocktwitsUser Mar. 24 at 1:40 AM

$ADCT RSI: 50.00, MACD: 0.0004 Vol: 0.25, MA20: 4.22, MA50: 3.99 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Apr 1, 2026, 4:05 PM EDT - 4 weeks ago

ADC Therapeutics Announces New Employee Inducement Grant

Mar 23, 2026, 7:00 PM EDT - 5 weeks ago

ADC Therapeutics Transcript: H.C. Wainwright Home Series

Mar 10, 2026, 8:30 AM EDT - 7 weeks ago

ADC Therapeutics Earnings Call Transcript: Q4 2025

Mar 10, 2026, 7:30 AM EDT - 7 weeks ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Mar 3, 2026, 11:50 AM EST - 2 months ago

ADC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 7:15 AM EST - 2 months ago

ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

Mar 2, 2026, 4:05 PM EST - 2 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Feb 24, 2026, 7:15 AM EST - 2 months ago

ADC Therapeutics to Participate in March Investor Conferences

Feb 23, 2026, 7:15 AM EST - 2 months ago

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement

Jan 15, 2026, 1:30 PM EST - 3 months ago

ADC Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 3 months ago

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

Jan 8, 2026, 7:15 AM EST - 3 months ago

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 5 months ago

ADC Therapeutics Transcript: Study Update

$ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 3, 2025, 7:30 AM EST - 5 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Dec 2, 2025, 4:05 PM EST - 5 months ago

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

Nov 19, 2025, 7:30 AM EST - 5 months ago

ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 1:30 PM EST - 6 months ago

ADC Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

ADC Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 7:30 AM EST - 6 months ago

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 3, 2025, 7:15 AM EST - 6 months ago

ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025

Oct 27, 2025, 7:15 AM EDT - 6 months ago

ADC Therapeutics to Present at November Investor Conferences

Oct 13, 2025, 7:30 AM EDT - 7 months ago

ADC Therapeutics Announces $60 Million Private Placement

Sep 3, 2025, 9:10 AM EDT - 8 months ago

ADC Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:15 AM EDT - 8 months ago

ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025

Aug 12, 2025, 8:30 AM EDT - 9 months ago

ADC Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 7:30 AM EDT - 9 months ago

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 5, 2025, 4:05 PM EDT - 9 months ago

ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025

Jul 1, 2025, 4:05 PM EDT - 10 months ago

ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

Jun 16, 2025, 7:15 AM EDT - 11 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Jun 12, 2025, 8:00 AM EDT - 11 months ago

ADC Therapeutics Transcript: Study Update

Jun 12, 2025, 6:45 AM EDT - 11 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

Jun 12, 2025, 6:30 AM EDT - 11 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

May 21, 2025, 10:30 AM EDT - 1 year ago

ADC Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

May 14, 2025, 7:45 AM EDT - 1 year ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

May 8, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Apr 28, 2025, 7:00 AM EDT - 1 year ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Apr 8, 2025, 8:00 AM EDT - 1 year ago

ADC Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Mar 25, 2025, 5:30 PM EDT - 1 year ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Mar 20, 2025, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Feb 6, 2025, 2:00 PM EST - 1 year ago

ADC Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:15 AM EST - 1 year ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 30, 2024, 4:30 PM EST - 1 year ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

Dec 11, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Transcript: Study Update

$ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma$

Dec 11, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

$ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma$

Dec 9, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Dec 6, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Nov 19, 2024, 6:00 AM EST - 1 year ago

ADC Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 11, 2024, 11:00 AM EST - 1 year ago

ADC Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 8, 2024, 1:14 PM EST - 1 year ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Nov 7, 2024, 8:30 AM EST - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Nov 5, 2024, 9:47 AM EST - 1 year ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Oct 31, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Sep 18, 2024, 11:30 AM EDT - 1 year ago

ADC Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

ADC Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 8:30 AM EDT - 1 year ago

ADC Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Jul 30, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Jul 8, 2024, 2:00 AM EDT - 1 year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Jun 27, 2024, 7:15 AM EDT - 1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Jun 6, 2024, 11:30 AM EDT - 2 years ago

ADC Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 20, 2024, 2:00 PM EDT - 2 years ago

ADC Therapeutics Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 14, 2024, 1:35 PM EDT - 2 years ago

ADC Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 7:15 AM EDT - 2 years ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

May 6, 2024, 8:30 AM EDT - 2 years ago

ADC Therapeutics Earnings Call Transcript: Q1 2024

May 6, 2024, 7:30 AM EDT - 2 years ago

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

Apr 9, 2024, 4:00 PM EDT - 2 years ago

ADC Therapeutics Transcript: Status Update

Mar 13, 2024, 8:30 AM EDT - 2 years ago

ADC Therapeutics Earnings Call Transcript: Q4 2023

Mar 12, 2024, 9:30 AM EDT - 2 years ago

ADC Therapeutics Transcript: Guggenheim 5th Annual Healthy Altitudes Summit

Mar 5, 2024, 9:50 AM EST - 2 years ago

ADC Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Nov 14, 2023, 5:00 AM EST - 2 years ago

ADC Therapeutics Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

ADC Therapeutics Earnings Call Transcript: Q3 2023

Sep 11, 2023, 2:15 PM EDT - 2 years ago

ADC Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 8, 2023, 8:30 AM EDT - 2 years ago

ADC Therapeutics Earnings Call Transcript: Q2 2023

May 9, 2023, 8:30 AM EDT - 3 years ago

ADC Therapeutics Earnings Call Transcript: Q1 2023

Feb 28, 2023, 9:30 AM EST - 3 years ago

ADC Therapeutics Earnings Call Transcript: Q4 2022

Nov 8, 2022, 9:30 AM EST - 3 years ago

ADC Therapeutics Earnings Call Transcript: Q3 2022

Aug 9, 2022, 8:30 AM EDT - 4 years ago

ADC Therapeutics Earnings Call Transcript: Q2 2022

May 9, 2022, 8:30 AM EDT - 4 years ago

ADC Therapeutics Earnings Call Transcript: Q1 2022

Mar 3, 2022, 9:30 AM EST - 4 years ago

ADC Therapeutics Earnings Call Transcript: Q4 2021

Feb 8, 2022, 10:00 AM EST - 4 years ago

ADC Therapeutics Transcript: Status Update

Nov 2, 2021, 9:30 AM EDT - 4 years ago

ADC Therapeutics Earnings Call Transcript: Q3 2021

Aug 3, 2021, 8:30 AM EDT - 5 years ago

ADC Therapeutics Earnings Call Transcript: Q2 2021

May 6, 2021, 8:30 AM EDT - 5 years ago

ADC Therapeutics Earnings Call Transcript: Q1 2021

Apr 23, 2021, 4:00 PM EDT - 5 years ago

ADC Therapeutics Transcript: Status Update

Mar 18, 2021, 9:30 AM EDT - 5 years ago

ADC Therapeutics Earnings Call Transcript: Q4 2020

Nov 12, 2020, 9:30 AM EST - 5 years ago

ADC Therapeutics Earnings Call Transcript: Q3 2020

Aug 18, 2020, 8:30 AM EDT - 6 years ago

ADC Therapeutics Earnings Call Transcript: Q2 2020

Jun 12, 2020, 8:30 AM EDT - 6 years ago

ADC Therapeutics Transcript: Investor Update

Rox22 Apr. 29 at 12:41 PM

0 · Reply

fmalad Apr. 24 at 11:18 PM

2 · Reply

WycklyTrader Apr. 24 at 5:33 PM

0 · Reply

scalpemfast Apr. 16 at 3:18 PM

$ADCT waking up

0 · Reply

BiotechGoldenEra Apr. 16 at 2:40 AM

$ADCT wasup wasup wasup mother fucka where my money at

0 · Reply

Bdorris2 Apr. 15 at 8:43 PM

$ADCT news? I don’t see any

2 · Reply

Jay_snf Apr. 15 at 8:01 PM

$ADCT

0 · Reply

SamHot Apr. 7 at 1:36 PM

$ADCT HOLD TIGHT

0 · Reply

focafoca99 Apr. 1 at 9:48 PM

$ADCT granted a new employee inducement option covering 17,000 shares.

0 · Reply

OfficialStocktwitsUser Mar. 24 at 1:40 AM

0 · Reply

SamHot Mar. 12 at 3:03 PM

$ADCT opportunity to buy a little more

0 · Reply

Gabriel_DS Mar. 12 at 2:31 PM

$ADCT did I miss something? Don't say market

0 · Reply

fmalad Mar. 12 at 5:04 AM

$ADCT lotus 5 we go to 10 buyout before lotus 7 we go to 28. Buyout after lotus 7 we go 30-35. No partnership. Hedge fund owners want cash offer!

1 · Reply

scalpemfast Mar. 12 at 1:59 AM

$ADCT , $AMD, $NVDA ADCT needs to be on your screen . It’s growing !!!

0 · Reply

scalpemfast Mar. 12 at 1:56 AM

$ADCT let’s get over $5 and open it up a little. Get on the gas !!!⛽️

0 · Reply

scalpemfast Mar. 11 at 2:08 AM

$ADCT buyout

0 · Reply

scalpemfast Mar. 11 at 1:39 AM

$ADCT buyout coming

1 · Reply

Nerevarine Mar. 10 at 5:27 PM

$ADCT Finally some good price action for this stellar company been in this for a while

0 · Reply

Rox22 Mar. 10 at 1:16 PM

$ADCT good call. Revenues up, costs down (and projected to decrease as studies wrap up). Data looks to be on timeline. Biggest take is of data goes well the market share they predict is very conservative, 10% of second line patients, which is why they have as a mini therapy currently. If data is differentiating (which the current numbers are) could be much higher % of second treatment protocols and the 600M-1billion opportunity could be much higher. Smart they are conservative, but they will adjust once they get the actual top line data. Good call! Suggest you read the transcript if you are invested here.

1 · Reply

StocktwitsEarnings Mar. 10 at 12:06 PM

$ADCT Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.04 up 86.21% YoY • Reported revenue of $23.06M up 36.36% YoY • ADC Therapeutics expects topline LOTIS-5 results in 2Q 2026, with full data for LOTIS-5 and LOTIS-7 by year-end 2026, and anticipates cash runway at least into 2028, supporting potential regulatory approval for LOTIS-5 in mid-2027.

0 · Reply

fmalad Mar. 10 at 4:45 AM

$ADCT earnings should be inline tomorrow. Maybe to the upside!

0 · Reply

Market Cap	479.51M
Revenue (ttm)	81.36M
Net Income (ttm)	-142.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-175.30%
Debt to Equity Ratio	-0.62

Volume	946,800
Avg Vol	915,910
Day's Range	N/A - N/A
Shares Out	127.19M
Stochastic %K	14%
Beta	1.94
Analysts	Strong Sell
Price Target	$8.00